For ER+ breast cancer patients who have received endocrine therapy, the AMHR2 gene expression levels of the responding group and the non-responding group are similar, and the ROC P-value and Mann–Whitney test P-value both are over 0.05 (Fig. 6A). The gene discussed is AMHR2; the disease is breast carcinoma.